Off‑the‑shelf and on‑target: how iPSC‑derived CAR‑T cells could democratize autoimmune cell therapy

“The future of autoimmunity is being reprogrammed in real time, and iPSC CAR‑T cells are helping to write the code.”

Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights, speaks with John (Bobby) Goulding, Director, Corporate Strategy, Fate Therapeutics, who takes an in‑depth look at induced pluripotent stem cell (iPSC)-derived allogeneic CAR‑T cells and their potential clinical application in autoimmune disease, including safety‑by‑design considerations, clinical trial considerations, manufacturing scalability, and democratizing outpatient access.

Please enter your email to access content Read now